Encompass Health Corporation (EHC) Up 4.7% — Is This Setup Too Good to Pass Up?
Encompass Health Corporation (EHC) is rallying this Thursday, last changing hands at $127.79 on the NYSE. That is a $5.70 gain over the prior close of $122.09. The advance puts the stock within roughly 1.7% of its 52-week high of $129.96, a level it reached only two weeks ago on October 15, 2026. That leaves EHC in striking distance of fresh highs as investors reward a quarter that cleared expectations on nearly every line.
About 505,985 shares have traded so far in the session, compared with a 90-day average of roughly 995,944. Turnover stands at about half of a typical full day with the regular session still open.
Why Encompass Health Corporation Price is Moving Higher
The driver is Encompass Health's Q3 2026 report, released on October 28. The company beat estimates and raised its full-year outlook. Adjusted EPS came in at $1.52 against a $1.36 consensus, a 23.6% jump from $1.23 a year earlier. Revenue reached $1.6095 billion, ahead of the roughly $1.60 billion analysts expected and up 8.9% from $1.4775 billion in the prior-year quarter. Net income attributable to the company rose to $149.9 million from $126.5 million. Discharges climbed 5.7% to 69,605, which confirms the growth came from rising patient volume rather than pricing alone.
Profitability improved alongside the top line. Adjusted EBITDA grew 15.5% to $346.6 million, or about 21.5% of revenue, up from 20.3% a year ago. Earnings are growing faster than revenue, so the business is converting each new admission into more profit.
Management then raised all three of its guidance figures for 2026 — the adjusted EPS range moved to $6.23–$6.37 from $6.02–$6.25. Revenue guidance rose to $6.45 billion–$6.50 billion from $6.41 billion–$6.49 billion. Adjusted EBITDA guidance increased to $1.395 billion–$1.415 billion from $1.365 billion–$1.395 billion.
Raising the bottom end of every range this late in the year signals real confidence in the fourth quarter. Broad Health Care strength added support, with the Health Care ETF (XLV) up 2.73% in the morning session. Facility operator HCA Healthcare, Inc. (HCA) gained 2.69% and Cardinal Health, Inc. (CAH) rose 1.77%. Still, EHC's 4.67% move outpaced the group, and that extra gain traces directly to the earnings beat and higher guidance.
What is the Encompass Health Corporation Rating - Should I Buy?
Weiss Ratings assigns EHC a B rating. Current recommendation is Buy. That rating reflects a company firing on all fundamental cylinders, and this week's results give the recommendation fresh support.
The core business case rests on three Excellent ratings: Growth, Efficiency and Solvency.
The Growth Index rating is backed by 9.58% revenue growth. For a provider of rehabilitation care, that pace is notable because it is driven by admissions rather than acquisitions or one-time pricing. The quarter's 5.7% discharge increase and 23.6% adjusted EPS gain show that momentum is accelerating.
The Excellent rating on the Efficiency Index is supported by a 24.97% ROE. That is a standout return for an operator that owns and runs a large network of hospitals.
A 10.00% profit margin backs the same conclusion. Many facility-based providers would struggle to reach that level under heavy Medicare exposure and labor costs.
The Excellent Solvency Index rating shows the balance sheet can fund new hospital openings without strain. That capacity is what allows management to keep expanding its bed count.
Where the picture becomes more nuanced is on the market-facing dimensions. The Good rating on the Total Return Index reflects a stock that has rewarded holders and now trades close to its 52-week high. It stops short of Excellent mainly because of the dividend, which yields just 0.64%. That modest payout also explains the Fair rating on the Dividend Index: EHC is a growth-and-reinvestment story rather than an income holding.
The Fair Volatility Index rating shows the shares can move sharply on news. Today's earnings-driven jump of nearly 5% is a clear example. At a forward P/E of 19.88, the stock is priced for continued execution, and that sensitivity to results is the main reason the overall rating sits at B rather than higher.
Within the Health Care sector, Encompass Health is on par with McKesson Corporation (MCK, B) and Cencora, Inc. (COR, B). It ranks ahead of Medtronic plc (MDT, B-) and HCA Healthcare, Inc. (HCA, B-). Cardinal Health, Inc. (CAH, B+) holds a modest edge, which places EHC firmly among the stronger names in a well-rated group.
About Encompass Health Corporation
Encompass Health Corporation (EHC) is a Health Care company and the largest owner and operator of inpatient rehabilitation hospitals in the United States. The company is headquartered in Birmingham, Alabama, and traces its roots to HealthSouth, founded in 1984. It took its current name and focused fully on facility-based rehabilitation after spinning off its home health and hospice business as Enhabit in 2022. Its network now spans more than 160 hospitals across dozens of states and Puerto Rico.
The company provides intensive inpatient rehabilitation for patients recovering from serious medical events. These include stroke, brain and spinal cord injuries, hip fractures, amputations, neurological disorders, and cardiac and pulmonary conditions. Patients typically receive several hours of physical, occupational and speech therapy each day under physician oversight, delivered by interdisciplinary clinical teams. Medicare is the largest payer, and an aging U.S. population creates a long runway of demand for post-acute recovery care.
Encompass Health's competitive advantages start with scale and expansion. The company adds capacity steadily through new hospital builds, bed additions to existing sites, and joint ventures with acute-care health systems. Those partnerships give it a steady flow of referrals and strengthen relationships with major hospital operators in local markets. Standardized clinical protocols, proprietary data and analytics, and a strong record on quality outcomes help it win referrals and manage costs. Smaller rehabilitation operators find that combination difficult to match.
Investor Outlook
Encompass Health Corporation (EHC) carries a Weiss Rating of B (Buy), and this quarter's beat-and-raise reinforces the case for a business growing earnings faster than revenue. Investors should watch whether discharge growth holds near the 5.7% pace and whether the 21.5% adjusted EBITDA margin carries into Q4 as the company delivers against its raised $6.23–$6.37 EPS range. A move above the $129.96 52-week high would confirm the market's renewed enthusiasm. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--